Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
As Capricor Therapeutics awaits a pivotal decision for its embattled Duchenne muscular dystrophy cell therapy deramiocel, the biotech revealed it…
Category: Capricor
Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
Capricor Therapeutics’ operating expenses jumped 70% in the third quarter as the company scaled up manufacturing and otherwise prepared to…